CABA — Cabaletta Bio, Inc. stock price, charts and financials

Latest market price

2.76

-0.03-1.16%

Overview Short InterestFilings

CABAQT72Cabaletta Bio, Inc.·NASDAQ

Overview Short InterestFilings

2.76-1.16%

Loading chart...

Signal & projected range

Short-squeeze setupHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

AUPH-2.33%$15.48 MESO+4.23%$16.61 ZBIO-0.58%$32.24 GHRS-1.72%$29.75 TSHA-1.45%$6.46 STOK-1.44%$32.24 ABCL+36.08%$9.43 VRDN-2.67%$22.96

Snapshot

Index	-	P/E	-	EPS (ttm)	-	Insider Own	4.53%	Shs Outstand	163.05M	Perf Week	4.10%

Market Cap	454.92M	Forward P/E	-	EPS next Y	-1.24	Insider Trans	0.00%	Shs Float	142.90M	Perf Month	-10.58%

Enterprise Value	364.74M	PEG	-	EPS next Q	-	Inst Own	-	Short Float	28.70%	Perf Quarter	-30.25%

Income	-255.35M	P/S	0.00	EPS this Y	-	Inst Trans	-	Short Ratio	8.31	Perf Half Y	19.74%

Sales	0.00	P/B	3.03	EPS next Y	9.61%	ROA	-118.42%	Short Interest	41.01M	Perf YTD	27.40%

Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-131.58%	52W High	4.18 -34.04%	Perf Year	92.41%

Cash/sh	-	P/FCF	-	EPS past 3/5Y	-	ROIC	-138.26%	52W Low	1.25 121.43%	Perf 3Y	-77.61%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	0.00%	Volatility	4.92% 5.45%	Perf 5Y	-62.60%

Dividend TTM	-	EV/Sales	0.00	EPS Y/Y TTM	16.24%	Oper. Margin	0.00%	ATR (14)	0.17	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	2.95	Sales Y/Y TTM	-	Profit Margin	0.00%	RSI (14)	48.28	Recom	2.17

Dividend Gr. 3/5Y	-	Current Ratio	2.95	EPS Q/Q	45.07%	SMA20	2.14%	Beta	3.20	Target Price	16.33

Payout	0.00%	Debt/Eq	0.26	Sales Q/Q	-	SMA50	-6.75%	Rel Volume	0.61	Prev Close	2.79

Employees	156	LT Debt/Eq	0.03	Earnings	Nov 05	SMA200	-2.38%	Avg Volume	4.44M	Price	2.76

IPO Date	Oct 25, 2019	Option/Short	No / Yes	EPS/Sales Surpr.	2.59% -	Net Debt/EBITDA	0.53	Volume	2,695,983	Change	-1.16%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Dec-20-24	Downgrade	Evercore ISI Group	Outperform → In Line
Dec-19-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Mar-21-24	Reiterated	Stifel Nicolaus
Jan-27-23	Upgrade	Morgan Stanley	Equal Weight → Overweight
Jan-03-23	Reiterated	Wells Fargo	Overweight
Aug-30-22	Downgrade	Morgan Stanley	Overweight → Equal Weight	$3.00

Latest News

Jun-26-26

Jun-26-2607:30AM

Cabaletta Bio: The Market Sold The EULAR News, I'm BuyingSeekingAlpha

Company

Cabaletta Bio, Inc. is a biotechnology firm in the clinical development stage, specializing in the invention and advancement of sophisticated engineered T cell therapies. Its core mission is to treat autoimmune diseases where B cells are implicated in producing harmful autoantibodies. The company's unique chimeric autoantibody receptor (CAAR) T cell platform is engineered to precisely target and eradicate these specific disease-causing B cells. Leading its pipeline is DSG3-CAART, which is currently in Phase I clinical trials. This candidate is being assessed for efficacy in two distinct conditions: mucosal pemphigus vulgaris, an autoimmune blistering skin disorder, and Hemophilia A in patients exhibiting Factor VIII alloantibodies. Cabaletta's broader product candidate portfolio also includes MuSK-CAART, a preclinical asset aimed at a particular subset of myasthenia gravis patients; FVIII-CAART, in the discovery phase for another subgroup of Hemophilia A sufferers; and DSG3/1-CAART, also a discovery-stage program, designed for mucocutaneous pemphigus vulgaris. The company maintains strategic alliances, including a collaboration with the University of Pennsylvania and a research pact with The Regents of the University of California. Founded in 2017 as Tycho Therapeutics, Inc., it adopted the name Cabaletta Bio, Inc. in August 2018 and is based in Philadelphia, Pennsylvania.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018	FY 2017 12/31/2017
Total Revenue	0	0	0	—	—	—	—	—	—
Cost of Goods Sold Incl. D&A	0	0	0	—	—	—	—	—	—
Gross Profit	0	0	0	—	—	—	—	—	—
Selling, General and Administrative Excl. Other	30	28	19	—	—	—	—	—	—
Research and Development	143	97	55	—	—	—	—	—	—
Other Operating Expense	-1	0	1	—	—	—	—	—	—
Operating Income	-172	-125	-75	—	—	—	—	—	—
Interest Expense	2	1	0	—	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	6	10	7	—	—	—	—	—	—
Net Income Before Taxes	-168	-116	-68	—	—	—	—	—	—
Income Taxes	0	0	0	—	—	—	—	—	—
Consolidated Net Income	-168	-116	-68	—	—	—	—	—	—
Net Income From Continuing Operations	-168	-116	-68	—	—	—	—	—	—
Net Income	-168	-116	-68	—	—	—	—	—	—
EPS (Recurring)	-1.64	-2.34	-1.65	—	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	-1.64	-2.34	-1.65	—	—	—	—	—	—
EPS (Diluted)	-1.64	-2.34	-1.65	—	—	—	—	—	—
EBITDA	-164	-113	-66	—	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	—	—	—	—	—	—	—	—	—
Gross Margin	—	—	—	—	—	—	—	—	—
Operating Margin	—	—	—	—	—	—	—	—	—
Net Margin	—	—	—	—	—	—	—	—	—
Shares Outstanding	102	50	41	—	—	—	—	—	—
Market Capitalization	223	114	931	—	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bollard Catherine	Director	Jan 21 '26	Buy	2.27	4,405	9,982	5,405	Jan 21
Simon Mark	Director	Jan 21 '26	Buy	2.28	11,061	25,261	147,205	Jan 21
Gerard Michael	General Counsel	Jan 21 '26	Buy	2.27	6,600	14,979	6,600	Jan 21
Nichtberger Steven	President & CEO	Jan 21 '26	Buy	2.24	45,000	100,778	1,031,483	Jan 21
Chang David J.	Chief Medical Officer	Jan 21 '26	Buy	2.26	8,800	19,888	8,800	Jan 21
Binder Gwendolyn	President, Science & Tech.	Jan 21 '26	Buy	2.19	11,312	24,763	31,312	Jan 21
Tomasello Shawn	Director	Jan 21 '26	Buy	2.21	22,725	50,322	22,725	Jan 21
Gavel Steve	Chief Commercial Officer	Jan 21 '26	Buy	2.27	22,170	50,215	22,170	Jan 21
Binder Gwendolyn	See Remarks	Jan 19 '24	Option Exercise	1.01	11,000	11,110	31,000	Jan 19
Binder Gwendolyn	See Remarks	Jan 19 '24	Sale	19.59	11,000	215,440	20,000	Jan 19
Binder Gwendolyn	See Remarks	Dec 19 '23	Option Exercise	1.01	11,000	11,110	31,000	Dec 19
Binder Gwendolyn	See Remarks	Dec 19 '23	Sale	21.89	11,000	240,789	20,000	Dec 19
Binder Gwendolyn	See Remarks	Nov 20 '23	Option Exercise	1.01	11,000	11,110	31,000	Nov 21
Binder Gwendolyn	See Remarks	Nov 20 '23	Sale	17.82	11,000	196,013	20,000	Nov 21
Binder Gwendolyn	See Remarks	Oct 19 '23	Option Exercise	1.01	11,000	11,110	31,000	Oct 19

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.